A Comprehensive Guide to Ketamine
Explore the burgeoning potential of ketamine infusion therapy with our comprehensive guide, designed to shed light on its therapeutic applications.
Esketamine (Spravato®) is a newer treatment for depression that works differently from traditional antidepressants. Delivered as a supervised nasal spray, it targets brain pathways involved in mood and can provide relief for people who have not responded to standard therapies.
For many people living with depression, standard treatments such as antidepressant medications and psychotherapy provide meaningful relief. However, a significant proportion of patients experience treatment-resistant depression (TRD) — where symptoms persist despite multiple treatment attempts.
Esketamine (Spravato®) represents a new class of treatment, offering a rapid, targeted approach for individuals who have not responded to conventional therapies.
What is Esketamine (Spravato®)?
Esketamine is a derivative of ketamine and is delivered as an intranasal spray (Spravato®). It is approved for use in treatment-resistant depression and is administered under strict medical supervision in accredited healthcare settings.
Unlike traditional antidepressants, which act on serotonin and noradrenaline pathways, esketamine (Spravato®) works on the glutamate system, targeting NMDA receptors in the brain. This allows it to influence mood pathways in a fundamentally different way.
How Does Esketamine (Spravato®) Work?
Esketamine (Spravato®) promotes rapid neuroplasticity — the brain’s ability to form new connections. It helps “reset” dysfunctional neural circuits involved in mood, stress, and emotional processing.
By increasing glutamate activity and enhancing synaptic connectivity, esketamine (Spravato®) can:
- Improve mood rapidly
- Reduce suicidal thinking
- Enhance emotional flexibility
- Support recovery in patients who have not responded to other treatments
This mechanism explains why many patients experience improvement within hours to days, rather than weeks.
Who is Esketamine (Spravato®) For?
Esketamine (Spravato®) is typically considered for patients who:
- Have treatment-resistant depression (failure of two or more antidepressants)
- Experience persistent depressive symptoms despite ongoing care
- May have suicidal ideation requiring rapid intervention
It is not a first-line treatment but is used when standard approaches have not been effective.
What to Expect During Treatment
Esketamine (Spravato®) is administered in a supervised clinical environment.
- The nasal spray is self-administered under clinician guidance
- Patients remain under observation for approximately 2 hours after dosing
- Blood pressure and mental state are monitored throughout
- Patients must arrange transport home and avoid driving for the rest of the day
Treatment usually follows an induction phase (twice weekly), followed by maintenance sessions spaced over time depending on response.
Effectiveness and Outcomes
Clinical trials have demonstrated that esketamine (Spravato®) can:
- Produce rapid antidepressant effects
- Improve symptoms in patients who have failed multiple treatments
- Reduce the severity and frequency of depressive episodes
Many patients report a shift in mood, thinking, and emotional responsiveness early in the treatment course, with continued improvement over time.
Side Effects and Safety
Esketamine (Spravato®) is generally well tolerated when administered under medical supervision.
Common side effects may include:
- Temporary dissociation or altered perception
- Dizziness or sedation
- Nausea
- Mild increases in blood pressure
These effects are typically short-lived and resolve during the monitoring period.
The Role of Esketamine (Spravato®) in Modern Mental Health Care
Esketamine (Spravato®) reflects a shift toward precision and rapid-acting treatments in psychiatry. For patients who have spent years cycling through medications without relief, it offers a new pathway forward.
Importantly, it is most effective when integrated into a broader care plan, including psychological support, medical oversight, and long-term follow-up.
Esketamine (Spravato®) is changing how we approach treatment-resistant depression — offering fast, evidence-based relief for those who have not responded to traditional therapies.
At Anodyne, we assess each patient individually to determine the most appropriate treatment pathway, ensuring care is safe, personalised, and clinically guided at every stage.
Disclaimer
Anodyne is a specialised health service focused on patient centred and novel approaches for pain management and mental health treatments.
Any advice posted on our blog, website, or app is of a general nature and for informational purposes only. It is not intended to replace or substitute for any medical or other advice.
Anodyne makes no representations or warranties and expressly disclaim any and all liability concerning any treatment, action by, or effect on any person following the general information offered or provided within or through the blog, website, or app. If you have specific concerns or a situation arises in which you require medical advice, you should consult with an appropriately trained and qualified medical practitioner.
Considering Esketamine (Spravato®) Treatment?
If you or your patient is struggling with treatment-resistant depression, our team can help determine whether esketamine or alternative therapies may be appropriate.
Make an enquiry: Opens in new window - Opens in new tab to learn more.
